150 Orphan Drug Indication Approvals Trusted to Perceptive IRT/RTSM

Trial sponsors rely on Perceptive eClinical IRT/RTSM to ensure patient supply during rare disease treatment development

Nottingham, England and Morrisville, NC – August 8, 2022 – Perceptive eClinical, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research, today announced it has achieved a milestone in supporting the clinical development of approved treatments for rare diseases. Clinical trial sponsors have relied on the Perceptive eClinical Interactive Response Technology (IRT) System in clinical trials supporting the approval of over 150 orphan drug indications, as designated by global regulators.

In rare disease trials, it is critical that trial supplies are available when patients are identified and that drug overage is minimized, which is challenging due to the larger numbers of investigative sites typically required to meet trial enrollment levels. Proven across 4,500+ studies, Perceptive eClinical has the most robust Randomization and Trial Supply Management (RTSM) system, routinely helping trial sponsors and CROs meet key milestones through reliable and flexible, on-time medication delivery.

“It is incredibly rewarding to see the work we do every day, supporting our clients’ important clinical development efforts, culminate in so many rare disease treatment options,” said Juan Munoz-Pujol, Vice President, IRT at Perceptive eClinical  “We’re honored that so many sponsors of orphan drug-designated trials have entrusted their randomization and drug supply management to Perceptive eClinical  IRT and continue to rely on our expertise as they bring safe and effective treatments to patients in critical need.”